Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR(+) breast cancer patients undergoing CDK4/6 treatment

Despite improved clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitor treatment has limited the success of this treatment in HR(+)HER2(−) metastatic breast cancer patients. Biomarkers are urgently needed, and longitudinal biomarker measurements may harbor more dynamic predictive a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dandachi, Nadia, Posch, Florian, Graf, Ricarda, Suppan, Christoph, Klocker, Eva Valentina, Müller, Hannah Deborah, Lindenmann, Jörg, Terbuch, Angelika, Heitzer, Ellen, Balic, Marija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410553/
https://www.ncbi.nlm.nih.gov/pubmed/33264486
http://dx.doi.org/10.1002/1878-0261.12870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410553/
https://www.ncbi.nlm.nih.gov/pubmed/33264486
http://dx.doi.org/10.1002/1878-0261.12870

Ejemplares similares